Prenetics completes $72M ACT Genomics exit

Prenetics (PRE) Global announced the official completion of its divestment of ACT Genomics to Delta Electronics. This transaction marks a final step in Prenetics’ strategic exit from the clinical diagnostics sector, enabling the company to dedicate its resources and attention to its rapidly expanding consumer health initiatives. The divestment significantly strengthens Prenetics’ financial position. Based on its ownership percentage, Prenetics has received $39.9 million in cash from the $72 million transaction, with an additional approximately $6.3 million held in escrow to be distributed over the next 18 months, bringing Prenetics’ total proceeds to $46 million. This brings Prenetics’ total cash reserves to over $60 million1, excluding its Bitcoin treasury, while maintaining a debt-free balance sheet. This strong financial foundation provides ample capital to fuel the growth of its flagship consumer health brand, IM8. The strategic shift allows Prenetics to fully capitalize on the remarkable momentum of IM8, which is on pace to achieve an annualized revenue run-rate of $100 million within its first 12 months of launch. This trajectory positions IM8 as one of the fastest-growing supplement brands in the history of the industry, demonstrating strong market demand and execution. In addition to its robust cash position, Prenetics also provided an update on its Bitcoin treasury strategy. The company now holds 255.4 BTC, with a current portfolio value of $31.6 million, representing a total investment of $27.8 million at an average cost of $108,972 per Bitcoin. This strategic allocation has generated an unrealized profit of $3.86 million, delivering a 13.9% return on the Bitcoin treasury investment, which initiated on June 16, 2025. Since August 1, 2025, Prenetics has implemented a disciplined approach of purchasing 1 BTC daily, with all holdings securely custodied at Kraken.